睿知中国疾病研究地图
候选清单0

正在招募多发性骨髓瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由厦门大学附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06581640,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Diagnosed with refractory/relapsed multiple myeloma through physical examination, pathological examination, laboratory tests, and imaging studies;

    入选标准第 2 条

    Flow cytometry or histology confirms positive BCMA expression in myeloma cells;

    入选标准第 3 条

  3. Received other experimental drug treatments within the last 3 months;

    排除标准第 11 条

  4. ECOG performance status score ≤2, KPS >60%;

    入选标准第 5 条

  5. Positive virology tests for hepatitis B, hepatitis C, HIV, syphilis, or cytomegalovirus;

    排除标准第 2 条

  6. Pregnant or nursing women, as well as women planning to become pregnant within the next six months;

    排除标准第 1 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06581640,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18-80 years, no gender restrictions;
  2. Diagnosed with refractory/relapsed multiple myeloma through physical examination, pathological examination, laboratory tests, and imaging studies;
  3. Flow cytometry or histology confirms positive BCMA expression in myeloma cells;
  4. As judged by the investigator, the expected survival time is >3 months;
  5. ECOG performance status score ≤2, KPS >60%;
  6. The patient has good liver, kidney, heart, and lung function: ALT and AST ≤2.5×ULN, those with liver involvement can be relaxed to ≤5×ULN; serum total bilirubin <34 μmol/L; creatinine clearance rate >30 mL/min; heart ejection fraction (EF) ≥40%, no pericardial effusion and significant arrhythmia; indoor SpO2 ≥92%;
  7. Peripheral blood lymphocyte absolute count ALC ≥0.5 ×10\^9/L, PLT >30×10\^9/L, Hb >80 g/L and has a single collection venous access, and there are no other contraindications for hematopoietic cell separation;
  8. Those with fertility must agree to use highly effective contraceptive methods;
  9. The subject or their legal guardian can understand and is willing to sign a written informed consent form voluntarily.

排除标准:Exclusion Criteria:

  1. Pregnant or nursing women, as well as women planning to become pregnant within the next six months;
  2. Positive virology tests for hepatitis B, hepatitis C, HIV, syphilis, or cytomegalovirus;
  3. History of other tumors (except for those with skin or cervical in situ cancers that have been cured by radical treatment and show no evidence of disease activity);
  4. Previously received treatment targeting BCMA;
  5. Underwent autologous hematopoietic stem cell transplantation within the last 6 weeks;
  6. Presence of uncontrolled active bacterial or fungal infection;
  7. Allergic to research-related drugs or cell components;
  8. Presence of active autoimmune diseases;
  9. Currently have unstable or active ulcers or gastrointestinal bleeding;
  10. Unable to cooperate with treatment and efficacy evaluation due to mental or psychological disorders;
  11. Received other experimental drug treatments within the last 3 months;
  12. The researcher believes that for other reasons, the individual is not suitable for the clinical trial.

引自 ClinicalTrials.gov, NCT06581640, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06581640,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06581640